Vivos Inc (RDGL) stock
RDGLOTCSurgical & Medical Instruments & ApparatusFiscal year ends December 31
$0.05−0.00 (-2.51%)
Close on Oct 19, 2026Market cap $23.61MP/E –Yield –
Vivos r&d expenses
Research and development expenses are spending on new products and technology.
Vivos's R&D Expenses for the twelve months ending Sep 30, 2026 was $176.07K, down 55.5% year over year. For fiscal 2025 it was $352.23K, up 8.5% from the year before. Over ten years it grew 8.9% a year on average. The highest annual figure on record is $732.70K in fiscal 2023.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $352.23K | +8.5% |
| FY2024 | Dec 31, 2024 | $324.63K | -55.7% |
| FY2023 | Dec 31, 2023 | $732.70K | +113.1% |
| FY2022 | Dec 31, 2022 | $343.80K | +19.9% |
| FY2021 | Dec 31, 2021 | $286.85K | +238.8% |
| FY2020 | Dec 31, 2020 | $84.67K | +25.3% |
| FY2019 | Dec 31, 2019 | $67.58K | -35.1% |
| FY2018 | Dec 31, 2018 | $104.21K | -48.7% |
| FY2017 | Dec 31, 2017 | $203.04K | -38.1% |
| FY2016 | Dec 31, 2016 | $328.03K | +119.2% |
| FY2015 | Dec 31, 2015 | $149.65K | +238.1% |
| FY2014 | Dec 31, 2014 | $44.27K | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $31.80K | -53.1% |
| Q2 FY2026 | Jun 30, 2026 | $49.18K | -54.4% |
| Q1 FY2026 | Mar 31, 2026 | $37.92K | -68.2% |
| Q4 FY2025 | Dec 31, 2025 | $57.17K | -43.4% |
| Q3 FY2025 | Sep 30, 2025 | $67.82K | +1.9% |
| Q2 FY2025 | Jun 30, 2025 | $107.97K | +8.3% |
| Q1 FY2025 | Mar 31, 2025 | $119.28K | +107.6% |
| Q4 FY2024 | Dec 31, 2024 | $100.97K | -76.6% |
| Q3 FY2024 | Sep 30, 2024 | $66.55K | -17.7% |
| Q2 FY2024 | Jun 30, 2024 | $99.66K | -42.5% |
| Q1 FY2024 | Mar 31, 2024 | $57.45K | +23.9% |
| Q4 FY2023 | Dec 31, 2023 | $432.11K | +1261.6% |
| Q3 FY2023 | Sep 30, 2023 | $80.86K | +14.3% |
| Q2 FY2023 | Jun 30, 2023 | $173.35K | +2.1% |
| Q1 FY2023 | Mar 31, 2023 | $46.38K | -36.1% |
| Q4 FY2022 | Dec 31, 2022 | $31.74K | -51.7% |
| Q3 FY2022 | Sep 30, 2022 | $70.77K | +16.3% |
| Q2 FY2022 | Jun 30, 2022 | $169.73K | +91.5% |
| Q1 FY2022 | Mar 31, 2022 | $72.57K | +1.2% |
| Q4 FY2021 | Dec 31, 2021 | $65.69K | +24.3% |
| Q3 FY2021 | Sep 30, 2021 | $60.83K | +322.9% |
| Q2 FY2021 | Jun 30, 2021 | $88.62K | +440.5% |
| Q1 FY2021 | Mar 31, 2021 | $71.70K | +6874.7% |
| Q4 FY2020 | Dec 31, 2020 | $52.86K | +880.7% |
| Q3 FY2020 | Sep 30, 2020 | $14.38K | -22.2% |
| Q2 FY2020 | Jun 30, 2020 | $16.40K | -18.1% |
| Q1 FY2020 | Mar 31, 2020 | $1.03K | -95.7% |
| Q4 FY2019 | Dec 31, 2019 | $5.39K | -80.2% |
| Q3 FY2019 | Sep 30, 2019 | $18.49K | +653.2% |
| Q2 FY2019 | Jun 30, 2019 | $20.02K | -52.1% |
| Q1 FY2019 | Mar 31, 2019 | $23.69K | -27.8% |
| Q4 FY2018 | Dec 31, 2018 | $27.17K | -40.8% |
| Q3 FY2018 | Sep 30, 2018 | $2.46K | -94.4% |
| Q2 FY2018 | Jun 30, 2018 | $41.77K | -48.1% |
| Q1 FY2018 | Mar 31, 2018 | $32.81K | – |
| Q4 FY2017 | Dec 31, 2017 | $45.87K | – |
| Q3 FY2017 | Sep 30, 2017 | $43.76K | – |
| Q2 FY2017 | Jun 30, 2017 | $80.52K | – |
| Q1 FY2017 | Mar 31, 2017 | $0 | – |
See a number that looks wrong?